Date: 2018-01-08
Type of information: Granting of the Breakthrough Therapy status
Product name: upadacitinib (ABT-494)
Compound: upadacitinib
Therapeutic area: Autoimmune diseases - Dermatological diseases
Action mechanism:
Company: Abbvie (USA - IL)
Disease: atopic dermatitis
Latest news:
Patents:
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news: